- Pfizer ( NYSE: PFE ) is said to have been involved in a bidding war with Johnson & Johnson ( NYSE: JNJ ) to acquire Global Blood Therapeutics ( NASDAQ: GBT ) before Pfizer won with its $5.4 billion offer.
- Johnson & Johnson ( JNJ ) is the unidentified "Company A" in a regulatory filing from Friday, according to a Bloomberg report from late Tuesday.
- Earlier this month Pfizer ( PFE ) agreed to buy sickle cell disease drug maker Global Blood Therapeutics ( GBT ) for $68.50/share.
For further details see:
Pfizer said to have had bidding war with Johnson & Johnson for Global Blood